Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance

被引:12
|
作者
Chinnadurai, Rajkumar [1 ,2 ]
Wu, Henry H. L. [2 ,3 ]
Cox, Eleanor [1 ]
Moore, Jayne [1 ]
Clough, Toni [1 ]
Lamerton, Elizabeth [1 ]
Donne, Rosie [1 ]
O'Riordan, Edmond [1 ]
Poulikakos, Dimitrios [1 ,2 ]
机构
[1] Northern Care Alliance NHS Fdn Trust, Dept Renal Med, Salford M6 8HD, Lancs, England
[2] Univ Manchester, Fac Biol Med & Hlth, Manchester M13 9PL, Lancs, England
[3] Lancashire Teaching Hosp NHS Fdn Trust, Dept Renal Med, Preston PR2 9HT, Lancs, England
关键词
COVID-19; vaccination; humoral response; hemodialysis; breakthrough infections; Delta variant; Omicron variant; HEPATITIS-B VACCINE; ANTIBODY-RESPONSE;
D O I
10.3390/vaccines10040498
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The advancement of COVID-19 vaccination programs globally has been viewed as an integral strategy to reduce both the number of COVID-19 cases and consequential complications of COVID-19, particularly for high-risk patient groups. There are limited data on the antibody response and protection from disease infection and severity in patients requiring hemodialysis (HD) following COVID-19 vaccination during the Delta and Omicron variant predominance. We conducted a study aiming to evaluate humoral immunity derived from two different COVID-19 vaccines administered to our in-centre HD population and investigated the characteristics of breakthrough COVID-19 infections occurring post-vaccination within this population. Methods: This is a prospective observational study including patients receiving HD at Salford Royal Hospital. The first and second doses of COVID-19 vaccinations (Pfizer BioNTech BNT162b2 or Oxford AstraZeneca ChAdOx1 nCoV-19) were administered to this patient cohort since January 2021. The incidence of any breakthrough COVID-19 infections occurring in double vaccinated patients between 1 April 2021 and 15 January 2022 was recorded. Patients were screened weekly with nasal and pharyngeal nasopharyngeal swabs for real-time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) for COVID-19, whilst SARS-CoV-2 antibody testing was performed alongside monthly routine HD bloods. Results: Four hundred eleven patients receiving HD were included in this study, of which 170 of 178 patients (95.5%) with available data on antibody status following two doses of the Pfizer BioNTech BNT162b2 vaccination had detectable antibody response, whilst this was the case for 97 of 101 patients (96.1%) who received two doses of the Oxford AstraZeneca ChAdOx1 nCoV-19 vaccine. For 12 seronegative patients who received a booster vaccine (third dose), nine seroconverted, while one remained negative and two were not tested. No statistically significant differences were observed with regards to antibody status between those receiving Pfizer BioNTech BNT162b2 and Oxford AstraZeneca ChAdOx1 nCoV-19 vaccines. Sixty-three of 353 patients with two doses of COVID-19 vaccination had breakthrough COVID-19 infection (40 during Delta and 23 during Omicron variant predominance). Of the 40 patients during the delta period, five were admitted into hospital and there were two reported deaths due to COVID-19-related illness. There were no COVID-19 associated hospitalizations or deaths during the Omicron variant predominance. Conclusions: The vast majority of HD patients who received two doses of the Pfizer BioNTech BNT162b2 or Oxford AstraZeneca ChAdOx1 nCoV-19 vaccinations developed detectable antibody responses. Our results support the value of booster vaccination with mRNA-based COVID-19 vaccine in HD patients and highlight the need for ongoing surveillance programmes with rRT-PCR and antibody testing for timely detection of positive cases.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Investigation of COVID-19 infection in patients with polymyalgia rheumatica during the predominance of the omicron variant
    Ma, Xinlei
    Xiao, Lanlan
    Wu, Jinzhi
    Xu, Guanhua
    Lin, Jin
    Chen, Weiqian
    [J]. RHEUMATOLOGY & AUTOIMMUNITY, 2024, 4 (03): : 174 - 179
  • [2] COVID-19 vaccination and breakthrough infections in patients with cancer
    Schmidt, A. L.
    Labaki, C.
    Hsu, C-Y
    Bakouny, Z.
    Balanchivadze, N.
    Berg, S. A.
    Blau, S.
    Daher, A.
    El Zarif, T.
    Friese, C. R.
    Griffiths, E. A.
    Hawley, J. E.
    Hayes-Lattin, B.
    Karivedu, V
    Latif, T.
    Mavromatis, B. H.
    McKay, R. R.
    Nagaraj, G.
    Nguyen, R. H.
    Panagiotou, O. A.
    Portuguese, A. J.
    Puc, M.
    Dutra, M. Santos
    Schroeder, B. A.
    Thakkar, A.
    Wulff-Burchfield, E. M.
    Mishra, S.
    Farmakiotis, D.
    Shyr, Yu
    Warner, J. L.
    Choueiri, T. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (03) : 340 - 346
  • [3] Delta variant neutralizing antibody response following maternal COVID-19 vaccination
    Craig, Amanda M.
    Pavon, Carolina G.
    Byrd, Alliyah
    Weaver, Kristin
    Swamy, Geeta K.
    Fouda, Genevieve
    Hughes, Brenna L.
    [J]. AMERICAN JOURNAL OF INFECTION CONTROL, 2024, 52 (02) : 252 - 254
  • [4] Humoral response to COVID-19 vaccination and maintenance hemodialysis: Correspondence
    Mungmunpuntipantip, Rujititka
    Wiwanitkitb, Viroj
    Kleebayoon, Amnuay
    [J]. MEDICINA CLINICA, 2023, 161 (07): : 315 - 316
  • [5] Characteristics and clinical outcomes of patients with COVID-19 recurrent infection during the omicron variant predominance
    Abuhasira, Ran
    Burrack, Nitzan
    Nesher, Lior
    Ostrovsky, Daniel
    Novack, Victor
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 114 : 131 - 134
  • [6] Continued effectiveness of COVID-19 vaccination among urban healthcare workers during delta variant predominance
    Lan, Fan-Yun
    Sidossis, Amalia
    Iliaki, Eirini
    Buley, Jane
    Nathan, Neetha
    Bruno-Murtha, Lou Ann
    Kales, Stefanos N.
    [J]. BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [7] Continued effectiveness of COVID-19 vaccination among urban healthcare workers during delta variant predominance
    Fan-Yun Lan
    Amalia Sidossis
    Eirini Iliaki
    Jane Buley
    Neetha Nathan
    Lou Ann Bruno-Murtha
    Stefanos N. Kales
    [J]. BMC Infectious Diseases, 22
  • [8] Multimorbidity and Frailty Are the Key Characteristics of Patients Hospitalized with COVID-19 Breakthrough Infection during Delta Variant Predominance in Italy: A Retrospective Study
    Ticinesi, Andrea
    Parise, Alberto
    Cerundolo, Nicoletta
    Nouvenne, Antonio
    Prati, Beatrice
    Chiussi, Giulia
    Guerra, Angela
    Meschi, Tiziana
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [9] COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant
    Martinez-Lopez, Joaquin
    de la Cruz, Javier
    Gil-Manso, Rodrigo
    Yuste, Victor Jimenez
    Aspa-Cilleruelo, Jose Maria
    Escobar, Cristian Escolano
    Lopez-Jimenez, Javier
    Duarte, Rafael
    Yerovi, Cristina Jacome
    Hernandez-Rivas, Jose-angel
    Herraez, Regina
    Quiroz-Cervantes, Keina
    Bustelos-Rodriguez, Rosalia
    Benavente, Celina
    Martinez Barranco, Pilar
    Bastos Oteiro, Mariana
    Alegre, Adrian
    Perez-Oteyza, Jaime
    Ruiz, Elena
    Marcheco-Pupo, Eriel Alexis
    Cedillo, Angel
    de Soto alvarez, Teresa
    Garcia Ramirez, Patricia
    Alonso Trillo, Rosalia
    Herrera, Pilar
    Bengochea Casado, Maria Luisa
    Arroyo Barea, Andres
    Martin De Bustamante, Jose Manuel
    Ortiz, Javier
    Calbacho Robles, Maria
    Garcia-Suarez, Julio
    Picardi, Marco
    [J]. CANCERS, 2024, 16 (02)
  • [10] PUBLIC HEALTH IMPACT OF UK COVID-19 BOOSTER VACCINATION DURING OMICRON PREDOMINANCE
    Mendes, D.
    Chapman, R.
    Aruffo, E.
    Gal, P.
    Nguyen, J. L.
    Hamson, E.
    DiFusco, M.
    Czudek, C.
    Yang, J.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S209 - S209